Rubin served as lead and corresponding author for a paper in The Lancet, which studied another drug called guselkumab, a monoclonal antibody that targets IL-23, the cytokine that drives many immune ...

"Managing ulcerative colitis often requires a personalized approach and ongoing adjustments based on the patient's response to therapy, especially for patients with more severe cases," noted lead ...